The importance of early treatment of the anaemia of chronic kidney disease

被引:21
|
作者
Eknoyan, G [1 ]
机构
[1] Baylor Coll Med, Dept Med, Renal Sect, Houston, TX 77030 USA
关键词
anaemia; cardiovascular diseased; chronic kidney disease; chronic renal failure; dialysis morbidity; dialysis mortality; epoetin; erythropoietin; kidney failure;
D O I
10.1093/ndt/16.suppl_5.45
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
The beneficial effects of treating the anaemia of dialysis-dependent patients with erythropoietin on the improvement of cardiac status, exercise capacity, cognitive function and quality of life are well established. Equally, if not more important is the reduction in morbidity and mortality that accompanies the treatment of anaemia with epoietin. These documented improvements in outcomes of care notwithstanding, mortality and morbidity due to cardiovascular disease (CVD) remain high in dialysis patients. Recent epidemiological evidence indicates that: (i) the prevalence of CVD is very high in patients at the start of dialysis (ii) pre-existing CVD is the major risk factor for mortality and morbidity on dialysis; (iii) CVD begins early in the course of kidney disease, shows an inverse relationship to kidney function and increases in prevalence and severity with progression of kidney disease; and (iv) corrective measures, which take 3-5 years to show a favourable effect, must be instituted well before the initiation of dialysis. Hypertension and anaemia, which develop in the course of progressive reduction in kidney function, are the principal risk factors for the prevalence of left ventricular hypertrophy (LVH) in those with chronic kidney disease, and their treatment has been shown to arrest or reverse LVH in these individuals. Whereas the treatment of hypertension early in the course of kidney disease has been incorporated into clinical practice, there has been reluctance in the treatment of anaemia because of the possibility of worsening kidney function with epoietin, as shown in rats. There is now convincing evidence that epoietin has no potential adverse effect on kidney function in humans. While the most compelling reason for the early treatment of the anaemia of kidney disease is its beneficial effect on cardiovascular function, other documented potential benefits are improvements in exercise capacity, cognitive function and quality of life.
引用
收藏
页码:45 / 49
页数:5
相关论文
共 50 条
  • [31] Anaemia as a risk factor for the progression of chronic kidney disease
    Deicher, R
    Hörl, WH
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (02): : 139 - 143
  • [32] Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
    Strippoli, G. F. M.
    Navaneethan, S. D.
    Craig, J. C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [33] New Strategies for Anaemia Management in Chronic Kidney Disease
    Locatelli, Francesco
    Del Vecchio, Lucia
    SCIENTIFIC ASPECTS OF DIALYSIS THERAPY: JSDT/ISBP ANNIVERSARY EDITION, 2017, 189 : 184 - 188
  • [34] Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
    Carrera, Fernando
    Burnier, Michel
    CLINICAL KIDNEY JOURNAL, 2009, 2 : I9 - I17
  • [35] Assessment of different detection methods of chronic kidney disease and their importance for an early diagnosis
    da Silva L.S.
    Cotta R.M.M.
    Moreira T.R.
    da Silva R.G.
    Rosa C.O.B.
    Journal of Public Health, 2015, 23 (4) : 223 - 229
  • [36] EARLY DAPAGLIFLOZIN UTILIZATION FOR CHRONIC KIDNEY DISEASE TREATMENT IN JAPAN
    Sofue, Tadashi
    Takeda, Masayoshi
    Koto, Ryo
    Wright, Jason
    Hong, Lai San
    Nan, Cassandra
    Wittbrodt, Eric
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I514 - I514
  • [37] Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
    Francesco Locatelli
    Roberto Minutolo
    Luca De Nicola
    Lucia Del Vecchio
    Drugs, 2022, 82 : 1565 - 1589
  • [38] Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors
    Locatelli, Francesco
    Minutolo, Roberto
    De Nicola, Luca
    Del Vecchio, Lucia
    DRUGS, 2022, 82 (16) : 1565 - 1589
  • [39] Evaluation of the indication of erythropoiesis stimulating agents in the treatment of anaemia associated with chronic kidney disease.
    Diez C, Perez
    Aznarez H, Navarro
    Arnal, Lou L. M.
    Sazatornil, Abad M. R.
    PHARMACEUTICAL CARE ESPANA, 2020, 22 (05): : 320 - 337
  • [40] Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia
    Kuragano, Takahiro
    Nakanishi, Takeshi
    RECENT ADVANCES IN DIALYSIS THERAPY IN JAPAN, 2018, 196 : 52 - 57